News >

Ibrutinib/Buparlisib Reaches Response in Half of NHL Cohort

Published: Thursday, Jun 07, 2018

blood cells Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma (NHL), according to findings from a phase I/II trial reported at the 2018 ASCO Annual Meeting.

Ibrutinib dose reduction was required in 35% of patients and buparlisib dose reduction in 41%. From 75% to 80% of patients required dose interruption for both drugs; 44% of patients had ibrutinib dose interruptions lasting at least 7 days, and 69% of patients had such interruptions with buparlisib.
Batlevi CL, De Frank S, Stewart C, et al. Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. J Clin Oncol. 2018;36 (suppl; abstr 7520).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication